Zhao Xun, Xu Chaoqun, Bera Chinmay, Arisar Fakhar Ali Qazi, Naghibzadeh Maryam, Azhie Amirhossein, Chen Shiyi, Xu Wei, Selzner Nazia, Tsien Cynthia, Lilly Leslie, Jaeckel Elmar, Bhat Mamatha
Ajmera Transplant Program, Toronto General Hospital, University Health Network, MaRS 9-9055, 585 University Avenue, Toronto, ON, M5G 2N2, Canada.
Division of Gastroenterology and Hepatology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Dig Dis Sci. 2025 Feb;70(2):543-551. doi: 10.1007/s10620-024-08781-3. Epub 2024 Dec 16.
Recent U.S. registry publications showed no improvement in long-term survival post-liver transplant in the last three decades. Cardiovascular disease was a leading cause of post-transplant mortality. This observation urged us to assess the trend in long-term survival of Canadian liver transplant recipients (LTR) in comparison to other countries, and examine trends in cause-specific mortality.
Consecutive adult subjects seen at the liver transplant center between September 1984 and December 2020 at the University Health Network (UHN) in Toronto, Canada, were reviewed. The study period was divided into seven 5-year eras. Comparisons between eras were made to assess trend over time. Cause-specific mortality were studied up to 10 years post-transplant.
In total, 2972 subjects were included. Overall, no significant improvement in long-term survival was observed over the seven eras. No significant difference in the risk of cardiovascular, malignancy, or infection-related mortality was observed across the eras. Significant improvements were observed in graft failure-related mortality. Compared to the age and sex matched general population, LTRs demonstrated a significantly higher mortality and shorter life expectancy.
Advances in transplant medicine over the last 35 years translated into a decrease in graft-related mortality. However, overall, there was no significant change in long-term survival considering all causes. Despite advances in post-transplant management, it has not led to a decrease in cardiovascular, malignancy or infection-related mortality in transplant recipients. Further research is warranted on the cause of stagnation in these areas and improving long-term post-transplant outcomes.
美国近期的登记处出版物显示,在过去三十年中,肝移植后的长期生存率没有改善。心血管疾病是移植后死亡的主要原因。这一观察结果促使我们评估加拿大肝移植受者(LTR)与其他国家相比的长期生存趋势,并研究特定原因死亡率的趋势。
回顾了1984年9月至2020年12月期间在加拿大多伦多大学健康网络(UHN)肝移植中心就诊的连续成年受试者。研究期分为七个5年时间段。对各时间段进行比较以评估随时间的趋势。研究了移植后长达10年的特定原因死亡率。
总共纳入了2972名受试者。总体而言,在这七个时间段内未观察到长期生存率有显著改善。各时间段中心血管、恶性肿瘤或感染相关死亡率的风险没有显著差异。在移植物衰竭相关死亡率方面观察到显著改善。与年龄和性别匹配的普通人群相比,肝移植受者的死亡率显著更高,预期寿命更短。
过去35年移植医学的进步转化为移植物相关死亡率的降低。然而,总体而言,考虑到所有原因,长期生存率没有显著变化。尽管移植后管理有所进步,但并未导致移植受者心血管、恶性肿瘤或感染相关死亡率的降低。有必要对这些领域停滞不前的原因以及改善移植后长期结局进行进一步研究。